Innovation Pharmaceuticals Inc (IPIX)

[mdphd2008]

In regards to the much anticipated prurisol data, I think we also need to entertain the most likely possibility that the prurisol data will be equivocal at best. This is a small phase 2 trial where it will not be easy to demonstrate statistical significance (each trial arm has relatively small numbers of patients). I will be happy to learn that there are no side effects and hints of efficacy which should hopefully compel the FDA to allow a larger phase 3.